FDA Clears Concerto Biosciences’ IND for Live Biotherapeutic Product to Treat AD
The U.S. Food and Drug Administration (FDA) has cleared Concerto Biosciences’ Investigational New Drug (IND) application to initiate a Phase 1, first-in-human trial of Ensemble No.2 (ENS-002), an investigational live biotherapeutic product (LBP) to treat atopic dermatitis (AD). The company discovered ENS-002 with kChip, its proprietary screening technology for identifying microbial, prebiotic, and postbiotic product candidates. […]